NCT07270237 · Memorial Sloan Kettering Cancer Center
A Study of Multiparametric Ultrasound Imaging Methods
What this study is about
The researchers are doing this study to see how well a type of ultrasound imaging called multiparametric ultrasound (mpUS), can be used to examine, evaluate, and provide information about different cancerous and non-cancerous tissue. The researchers will compare the results of mpUS imaging to standard ultrasound imaging and other standard tests.
View original scientific description
The researchers are doing this study to see how well a type of ultrasound imaging called multiparametric ultrasound (mpUS), can be used to examine, evaluate, and provide information about different cancerous and non-cancerous tissue. The researchers will compare the results of mpUS imaging to standard ultrasound imaging and other standard tests. mpUS imaging is a type of ultrasound imaging that combines different ultrasound methods and analysis to create a more detailed and accurate assessment of tissue. Standard ultrasound provides a basic image of tissue structure, but mpUS imaging can also show blood vessels, blood flow, and detailed tissue structure (microstructure). The researchers think that mpUS may be a better way for evaluating cancer because it combines different ultrasound methods to assess tissue.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Cohort 1 - Feasibility of multiparametric endoscopic ultrasound (mpEUS) imaging of patients at high-risk for pancreatic cancer: Patient Group: those having standard endoscopic ultrasounds because they are at high risk of pancreatic cancer Participants enrolled into the Memorial Sloan Kettering Cancer Center Pancreatic Registry protocol (IRB#: 02-102) will be eligible for this study. Specifically, related individuals without pancreatic cancer who are at-risk for developing pancreatic cancer and meet all of the following criteria (family health history will be self-reported):
- 10 years younger than the earliest pancreatic cancer diagnosis in the family
- Be at least 50 years old
- Be at least 40 years old if diagnosed with FAMMM syndrome (CDKN2A/p16) or Hereditary Pancreatitis (PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes)
- Be at least 35 years old if diagnosed with Peutz-Jeghers syndrome (STK11 aka LKB1)
- Not pregnant and not Nursing
- Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined by the project leader (Dr. Vineet Rolston)
- Must agree to be contacted for follow-up
- Must satisfy at least one of the following 4 criteria:
- Have at least two affected relatives who are a first-degree relative to each other, of whom at least one is a first degree relative to the individual OR have at least two affected first-degree relatives on the same side of the family.
- Have at least one first- or second-degree affected relative and have germline genetic test results that confirm a likely pathogenic or pathogenic variant in at least one of the following genes:
- APC (Familial Adenomatous Polyposis (FAP) and Attenuated FAP syndrome
- BRCA1(Hereditary Breast and Ovarian Cancer Symptoms)
- MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch Syndrome)
- TP53 (Li-Fraumeni Syndrome)
- Other established pancreatic cancer predisposition gene per project leader's discretion
- Have germline genetic test results that confirm a likely pathogenic or pathogenic variant in one or more of the following genes:
- CDKN2A/p16 (Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM))
- STK11 aka LKB1 (Peutz-Jeghers Syndrome)
- PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes per project leader's discretion
- ATM (ataxia telangiectasia mutated)
- BRCA 2(Hereditary Breast and Ovarian Cancer Symptoms)
- Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined the project leader (Dr. Vineet Rolston) Cohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma: Patient Group: those with pancreatic cancer having endoscopic ultrasound-guided biopsies Patients will be entered into the study if they meet the following criteria:
- Patients with pancreatic ductal adenocarcinoma
- Are undergoing endoscopic ultrasound-guided tissue core biopsy as part of their standard of care
- Not pregnant and not nursing Cohort 3 - Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging: Patient Group: those with a thyroid nodule that will be biopsied whether they have known cancer or not
- Are undergoing ultrasound-guided thyroid biopsy as part of their standard of care
- Not pregnant and not nursing Healthy Volunteers will be entered into the study if they meet the following criteria:
- No known cancer diagnosis or thyroid nodules
- Able to understand and give informed consent
- Not pregnant and not nursing
Exclusion criteria
- Cohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma:
- Unable to sign an informed consent for medical or other reasons; residents outside the continental United States
- Under 18 years of age Cohort 3 -Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging
- Unable to sign an informed consent for medical or other reasons; residents outside the continental United States
- Under 18 years of age
Where
- Basking Ridge, New Jersey
- Middletown, New Jersey
- Montvale, New Jersey
- Commack, New York
- Harrison, New York
- New York, New York
- Uniondale, New York
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Dec 12, 2025 · Source of record for eligibility and locations